Bicahis 20 Drug Interactions

Avoid concomitant use: Avoid concomitant use of bilastine with any of the following: Aclidinium, Azelastine (nasal), Cimetropium, Eluxadoline, Glucagon, Glycopyrrolate (oral inhalation), Ipratropium (oral inhalation), Levosulpiride, Nitroglycerin, Orphenadrine, Oxatomide, Oxomemazine, Paraldehyde, Potassium chloride, Thalidomide, Tiotropium, Umeclidinium.
Increased effect/Toxicity: Bilastine may increase the levels/effects of: Abobotulinumtoxin A, Alcohol (Ethyl), Analgesics (Opioid), Anticholinergic agents, Azelastine (Nasal), Blonanserin, Buprenorphine, Cimetropium, CNS Depressants, Eluxadoline, Flunitrazepam, Glucagon, Glycopyrrolate (Oral Inhalation), Hydrocodone, Methotrimeprazine, Metyrosine, Mirabegron, Mirtazapine, Onabotulinumtoxin A, Orphenadrine, Oxycodone, Paraldehyde, Piribedil, Potassium chloride, Pramipexole, Ramosetron, Rimabotulinumtoxin B, Ropinirole, Rotigotine; Selective Serotonin Reuptake Inhibitors, Suvorexant, Thalidomide, Thiazide and Thiazide-Like Diuretics, Tiotropium, Topiramate, Zolpidem.
The levels/effects of bilastine may be increased by: Aclidinium; Brimonidine (Topical); Canabis; Chloral Betaine; Chlormethiazole; Chlorphenesin Carbamate; Dimethindene (Topical); Doxylamine; Dronabinol; Droperidol; Hydroxyzine; Ipratropium (Oral inhalation) Kava Kava; Lofexidine; Lumacaftor, Magnesium sulfate, Methotrimeprazine; Mianserin; Minocycline; Nabione; Oxatomide; Oxomemazine; Perampanel; P-glycoprotein/ABCB1 Inhibitors; Pramlintide; Ranolazine; Rufinamide; Sodium oxybate; Tapentadol: Tetrahydrocannabinol; Trimeprazine; Umeclidinium.
Decreased effect: Bilastine may decrease the levels/effects of: Acetylcholinesterase inhibitors; Benzylpenicilloyl Polylysine; Betahistine; Gastrointestinal agents (Prokinetic); Hyaluronidase, Itopride, Levosulpiride; Nitroglycerin; Secretin.
The levels/effects of bilastine may be decreased by: Acetylcholinesterase inhibitor; Amphetamines; Grape fruit juice; Lumacaftor; P-glycoprotein/ABCB1 inducers.
Other drug-drug interaction: Interaction with ketoconazole or erythromycin: Concomitant intake of bilastine and ketoconazole or erythromycin increased bilastine AUC 2-fold and C_max 2-3 fold. These changes do not appear to affect the safety profile.
Interaction with diltiazem: Concomitant intake of bilastine and diltiazem increased C_max of bilastine by 50% and does not appear to affect the safety profile.
Food interaction: Food: Decreases bioavailability by 33%. Management: Administer 1 hour before or 2 hours after intake of food.
Grapefruit juice: Decreases bioavailability by 30%. This effect may also apply to other fruit juices. Management: Administer 1 hour before or 2 hours after intake of grapefruit juice or other fruit juices.